ReviewRSC advances2025
Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spirooxindole Derivatives as Emerging Scaffolds in Drug Discovery: Synthetic Strategies, Structure-Activity Relationship, and Biological Activities.ChemMedChem · 2026Review
- Identification of spiropyrrolidinoxindoles as SARS-CoV-2 main protease inhibitor hits from virtual screening.Journal of computer-aided molecular design · 2026Article
- Microwave-Assisted Organic Synthesis: An Eco-Friendly Method of Green Chemistry.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020-2025).RSC advances · 2025Review
- Synthesis and Biological Properties of Isatin-indole Hybrids: A Review.Mini reviews in medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Halogenated spirooxindoles have garnered increasing attention as promising targeted anticancer therapy agents, owing to their improved binding affinity and ability to engage diverse molecular targets. These compounds demonstrate notable anticancer activity across various human malignancies, attributed to their selectivity targeting and reduced toxicity profiles. Functioning as multitarget agents, halogenated spirooxindoles exert biological effects through mechanisms including kinase inhibition, disruption of the MDM2-p53 interaction, DNA-binding modulation, and activation of apoptosis pathways. Their multifaceted activity profile supports their potential as next-generation anticancer agents, suggesting that further studies will be required in this direction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.